Format

Send to

Choose Destination
Clin Neurol Neurosurg. 2018 Aug;171:26-33. doi: 10.1016/j.clineuro.2018.02.041. Epub 2018 Mar 9.

Crizotinib and erlotinib inhibits growth of c-Met+/EGFRvIII+ primary human glioblastoma xenografts.

Author information

1
Department of Neurology, The Hugo W. Moser Research Institute at Kennedy Krieger Inc., United States; Department of Neurosurgery, The Johns Hopkins University, School of Medicine, Baltimore, MD, United States; Department of Neurosurgery, Duke University Medical Center, Durham, NC, United States. Electronic address: rory.goodwin@duke.edu.
2
Department of Neurology, The Hugo W. Moser Research Institute at Kennedy Krieger Inc., United States; Department of Neurosurgery, The Johns Hopkins University, School of Medicine, Baltimore, MD, United States.
3
Department of Neurology, The Hugo W. Moser Research Institute at Kennedy Krieger Inc., United States.
4
Department of Neurology, The Hugo W. Moser Research Institute at Kennedy Krieger Inc., United States; Department of Neurology, The Johns Hopkins University, School of Medicine, Baltimore, MD, United States.
5
Department of Neurosurgery, The Johns Hopkins University, School of Medicine, Baltimore, MD, United States.

Abstract

OBJECTIVES:

Receptor tyrosine kinases (RTK), such as c-Met and epidermal growth factor receptor (EGFR), are implicated in the malignant progression of glioblastoma. Studies show that RTK systems can co-modulate distinct and overlapping oncogenic downstream signaling pathways. EGFRvIII, a constitutively activated EGFR deletion mutant variant, leads to increased tumor growth and diminishes the tumor growth response to HGF: c-Met pathway inhibitor therapy. Conversely, activation of the c-Met pathway diminishes the tumor growth response to EGFR pathway inhibitors. Previously we reported that EGFRvIII and c-Met pathway inhibitors synergize to inhibit tumor growth in isogenic GBM cell lines engineered to express EGFRvIII. More recently, studies suggest that despite targeting RTK signaling in glioblastoma multiforme, a subpopulation of stem-like tumor-propagating cells can persist to replenish the tumor cell population leading to tumor recurrence.

PATIENTS AND METHODS:

Mayo 39 and Mayo 59 xenograft lines were cultured and xenografts were maintained. Subcutaneous xenograft lines were serially passaged in nude mice to generate subcutaneous xenografts. Xenografts were implanted in 6-8 week old nude mice. Once tumors reached a substantial size (150 mm3), mice were randomly divided into 4 groups: 1) control vehicle, 2) Crizotinib (crizo), 3) Erlotinib (erlot), or 4) Crizotinib + Erlotinib, (n = 5 per group).

RESULTS:

Crizotinib (c-Met pathway inhibitor) and Erlotinib (EGFR pathway inhibitor) in combination significantly inhibited tumor growth, phospho-EGFRvIII, phospho-Met, phospho-AKT, phospho-MAPK, and neurosphere growth in Mayo 39 and Mayo 59 primary GBM subcutaneous xenografts. The expression of the stem cell markers Nestin, Musashi, Olig 2 and Sox2 were also significantly down-regulated by c-Met inhibition, but no additive down-regulation was seen by co-treatment with Erlotinib.

CONCLUSIONS:

These results are consistent with and corroborate our previous findings demonstrating that targeting these two parallel pathways with c-Met and EGFR inhibitor therapy provides substantial anti-tumor activity in glioblastoma models.

KEYWORDS:

Crizotinib; Epidermal growth factor receptor; Erlotinib; Glioblastoma; Primary xenograft; c-Met

PMID:
29803091
DOI:
10.1016/j.clineuro.2018.02.041
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center